The basics of the immunotherapeutic approach used here were published previously by our group and are based on the intratumoral injection of mannan anchored to the tumor cell surface via a biocompatible anchor for cell membrane (BAM), a mixture of toll-like receptor (TLR) ligands, and agonistic anti-CD40 monoclonal antibody (MBTA therapy). This evidence concerns the gene CD40 and neoplasm.